Sage drops a pair of late-stage tests for Bio­gen-part­nered de­pres­sion drug, rais­ing the stakes on a fi­nal tri­al

When Sage Ther­a­peu­tics’ star ex­per­i­men­tal de­pres­sion drug, zu­ra­nolone, failed the cru­cial MOUN­TAIN study, the biotech slammed the brakes on two oth­er piv­otal tri­als in or­der to re­think their de­sign.

Now that a sec­ond Phase III shot has proven a suc­cess, Sage has now de­cid­ed to scrap those tri­als al­to­geth­er.

The biotech dis­closed in a quar­ter­ly up­date that it’s “for­mal­ly ter­mi­nat­ing the RED­WOOD and RAIN­FOR­EST stud­ies,” which were first sus­pend­ed more than a year ago. RED­WOOD was de­signed to test a fixed sched­ule in­ter­mit­tent dos­ing of zu­ra­nolone 30mg, while RAIN­FOR­EST in­volved the same dose but en­rolled pa­tients with MDD and co-mor­bid in­som­nia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER